**Ryr1 gene**
ryanodine receptor 1

**Normal Function**

The *RYR1* gene provides instructions for making a protein called ryanodine receptor 1 (also called the RYR1 channel). This protein is part of a group of related proteins called ryanodine receptors, which form channels that, when turned on (activated), release positively charged calcium atoms (ions) from storage within cells. RYR1 channels play a critical role in muscles used for movement (skeletal muscles).

For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by an increase in the concentration of calcium ions inside muscle cells.

RYR1 channels are located in the membrane surrounding a structure in muscle cells called the sarcoplasmic reticulum. This structure stores calcium ions when muscles are at rest. In response to certain signals, the RYR1 channel releases calcium ions from the sarcoplasmic reticulum into the cell fluid. The resulting increase in calcium ion concentration in muscle cells stimulates muscles to contract, allowing the body to move. The process by which electrical signals trigger muscle contraction is called excitation-contraction (E-C) coupling.

**Health Conditions Related to Genetic Changes**

**Central core disease**

More than 100 mutations in the *RYR1* gene have been identified in people with central core disease. This condition is characterized by muscle weakness, primarily affecting the muscles near the center of the body (proximal muscles), such as the muscles in the upper legs and hips. Affected individuals also have an increased risk of malignant hyperthermia (described below).

Most of the *RYR1* gene mutations involved in central core disease affect single protein building blocks (amino acids) in critical regions of the ryanodine receptor 1 protein. These mutations change the structure of the RYR1 channel, which alters the normal flow of stored calcium ions within muscle cells. A disruption in calcium ion release prevents muscles from contracting normally, leading to the muscle weakness characteristic of central core disease.

Researchers have proposed two mechanisms to explain how *RYR1* gene mutations underlie muscle weakness in people with central core disease. Some genetic changes cause the RYR1 channel to be "leaky," allowing calcium ions to flow slowly but continually out of the sarcoplasmic reticulum. The leaky channels greatly reduce...
the amount of stored calcium ions. As a result, not enough calcium ions are available in the sarcoplasmic reticulum to trigger muscle contractions. Muscle weakness results from the inability of skeletal muscles to contract appropriately.

Other *RYR1* gene mutations change the structure of the RYR1 channel in a way that impedes the normal flow of calcium ions. Although the sarcoplasmic reticulum stores plenty of these ions, the receptor cannot release them in response to the usual signals. Without enough calcium ions flowing out of the sarcoplasmic reticulum at the appropriate time, muscles cannot contract normally and muscle weakness results. This mechanism is known as E-C uncoupling.

**Congenital fiber-type disproportion**

At least 11 mutations in the *RYR1* gene have been found to cause congenital fiber-type disproportion, a disorder that causes general muscle weakness that typically does not worsen over time. Some mutations change single amino acids in the ryanodine receptor 1 protein. Other *RYR1* gene mutations create a premature stop signal in the instructions for making the receptor, resulting in an abnormally short, nonfunctional protein. Researchers suspect that disruption of the RYR1 channel may play a role in the muscle weakness and other features of congenital fiber-type disproportion, although the role of *RYR1* gene mutations in this condition is unclear.

It is not yet clear whether people with congenital fiber-type disproportion caused by *RYR1* gene mutations have an increased risk of malignant hyperthermia (described below).

**Multiminicore disease**

More than 20 mutations in the *RYR1* gene have been found to cause atypical forms of multiminicore disease. Multiminicore disease is characterized by muscle weakness, and the atypical forms can have additional features. The condition is also associated with an increased risk of malignant hyperthermia (described below).

*RYR1* gene mutations involved in multiminicore disease change single amino acids in the ryanodine receptor 1 protein, which alters the structure and function of the protein. The effects of these changes are unclear. Some mutations may reduce the amount of ryanodine receptor 1 protein produced by the cell or lead to an unstable version of the protein. Other mutations may interfere with the normal regulation of the RYR1 channel. Researchers believe that some *RYR1* gene mutations change the shape of the channel in such a way that calcium ions cannot flow through properly. A disruption in calcium ion transport prevents muscles from contracting normally, leading to the muscle weakness characteristic of multiminicore disease.

**Malignant hyperthermia**

*RYR1* gene mutations are the most common genetic risk factor for malignant hyperthermia. Malignant hyperthermia is a severe reaction to particular anesthetic drugs that are often used during surgery and other invasive procedures. The reaction
involves a high fever (hyperthermia), a rapid heart rate (tachycardia), muscle rigidity, breakdown of muscle fibers (rhabdomyolysis), and increased acid levels in the blood and other tissues (acidosis). Complications can be life-threatening without prompt treatment.

At least 48 mutations in the \textit{RYR1} gene are known to increase the risk of malignant hyperthermia in people without features of a muscle disorder (such as central core disease or multiminicore disease, described above). Most of these mutations change single amino acids in important regions of the ryanodine receptor 1 protein. These mutations alter the structure of the RYR1 channel, causing it to open more easily and close more slowly in response to certain drugs (particularly some anesthetic gases and a type of muscle relaxant used during surgery). As a result, large amounts of calcium ions are released from the sarcoplasmic reticulum inside muscle cells. An overabundance of calcium ions activates processes that generate heat (leading to increased body temperature) and produce excess acid (leading to acidosis). An increase in calcium ion concentration within muscle cells also causes skeletal muscles to contract abnormally, which leads to muscle rigidity.

Many other changes in the \textit{RYR1} gene have been described in people with an increased risk of malignant hyperthermia. It is unclear, however, whether these variations are directly related to malignant hyperthermia risk.

\textbf{Centronuclear myopathy}

\textbf{Chromosomal Location}

Cytogenetic Location: 19q13.2, which is the long (q) arm of chromosome 19 at position 13.2

Molecular Location: base pairs 38,433,691 to 38,587,564 on chromosome 19 (\textit{Homo sapiens Updated Annotation Release 109.20200522, GRCh38.p13}) (NCBI)

\textbf{Other Names for This Gene}

- CCD
- MHS
• MHS1
• PPP1R137
• ryanodine receptor 1 (skeletal)
• ryanodine receptor type1
• RYDR
• RYR
• RYR-1
• RYR1_HUMAN
• sarcoplasmic reticulum calcium release channel
• skeletal muscle ryanodine receptor
• Skeletal muscle-type ryanodine receptor
• SKRR

Additional Information & Resources

Educational Resources
• Eurekah Bioscience Collection: Intracellular Ca2+ Release Channels
  https://www.ncbi.nlm.nih.gov/books/NBK5959/
• National Human Genome Research Institute: The Genomic Services Research Program (GSRP): Study of People with Unexpected Genetic Results
  https://www.genome.gov/Current-NHGRI-Clinical-Studies/Genomic-Services-Research-Program
• Neuromuscular Disease Center, Washington University: Central Core Disease
  https://neuromuscular.wustl.edu/syncm.html#cc
• Neuromuscular Disease Center, Washington University: Congenital Fiber Type Size Disproportion
  https://neuromuscular.wustl.edu/syncm.html#cftd
• Neuromuscular Disease Center, Washington University: Malignant Hyperthermia
  https://neuromuscular.wustl.edu/msys/myoglob.html#mh
• Neuromuscular Disease Center, Washington University: Multicore (Minicore) Disease
  https://neuromuscular.wustl.edu/syncm.html#multicore

Clinical Information from GeneReviews
• Malignant Hyperthermia Susceptibility
  https://www.ncbi.nlm.nih.gov/books/NBK1146
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28RYR1%5BTIAB%5D%29+OR+%28ryanodine+receptor+1%5BTIAB%5D%29%29+AND+%28%28ryr1%5BMAR%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5D

Catalog of Genes and Diseases from OMIM

- RYANODINE RECEPTOR 1
  http://omim.org/entry/180901

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/GC_RYR1.html

- ClinVar
  https://www.ncbi.nlm.nih.gov/clinvar?term=RYR1%5Bgene%5D

- HGNC Gene Symbol Report

- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:6261

- NCBI Gene

- UniProt
  https://www.uniprot.org/uniprot/P21817

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23919265
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751094/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15589992

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20583297
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17504518
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1887524/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17631035
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1947955/

  Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation- 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16958053

• Lyfenko AD, Goonasekera SA, Dirksen RT. Dynamic alterations in myoplasmic Ca2+ in malignant 
  1256-66. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15336973

• Riazi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post-Genomics Era: New 
  ALN.0000000000001878. Review. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28902675
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726912/

• Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16917943

• Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. 2003 
  Dec 19 [updated 2013 Jan 31]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, 
  Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® 
  www.ncbi.nlm.nih.gov/books/NBK1146/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301325

• Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16477617

• Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S, Zorzato F. 
  Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16084090

• Wu S, Ibarra MC, Malicdan MC, Murayama K, Ichihara Y, Kikuchi H, Nonaka I, Noguchi S, Hayashi 
  YK, Nishino I. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain. 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16621918
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17483490

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17365175

Reprinted from Genetics Home Reference:
  https://ghr.nlm.nih.gov/gene/RYR1

Reviewed: May 2020
Published: August 17, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services